Pakistan is witnessing a severe shortage of more than 100 essential medicines, including several life-saving drugs used to treat cancer, heart disease and other serious illnesses, amid prolonged delays by the federal government in approving revised medicine prices, as reported by Dawn.
According to a report, the Drug Regulatory Authority of
Pakistan (Drap) recommended revised prices for 105 hardship category medicines more than two years ago after concluding that soaring production costs had made their manufacturing commercially unviable.
However, the proposals remain pending with the federal cabinet, resulting in reduced production and widespread shortages across the country.